Irrespective of a history of ASCVD, finerenone reduced the risk of CV events and CKD progression compared with placebo in patients with T2DM and CKD, as shown in a FIDELITY subgroup analysis.

Finerenone, a non-steroidal MRA, has been approved for the treatment of CKD in adults with T2DM. Previously, the FIDELITY study showed that finerenone improves cardiorenal outcomes in these patients. But does this also apply to HF-related outcomes?

Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.

RAASi therapy is a critical component of HF management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. Prof. Kosiborod and Prof Stack discuss how to manage hyperkalemia while continuing to up-titrate RAASi therapy in patients with HFrEF & CKD.

The FIDELITY pooled analysis findings demonstrated benefits in CV and kidney outcomes with the nonsteroidal MRA finerenone. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of CKD, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.

Diabetic nephropathy is one of the leading causes of ESRD. Three experts explore recent data on the use of nonsteroidal MRAs and discuss how to prevent deterioration of renal function and improve CV outcomes across the spectrum of renal decline.

AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.

AHA 2022 David Preiss shares the results from the EMPA-KIDNEY trial and a collaborative meta-analysis including EMPA-KIDNEY and 12 other major SGLT2i trials.

The EMPULSE trial showed that treatment with empagliflozin for 90 days results in a clinical benefit in patients hospitalized for acute HF, compared with placebo. Is this effect dependent on renal function? And what are the renal effects of empagliflozin in acute HF?

By analysis of pooled plasma samples of 1134 patients from the EMPEROR-Reduced and EMPEROR-Preserved trials using large-scale proteomics, the authors identified several biological effects of empagliflozin on the heart and kidneys.

Using data from the CANTOS trial, the investigators assessed the relative contributions of hyperlipidemia and inflammation to CV clinical outcomes in atherosclerosis patients on statin therapy, stratified by eGFR.

EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.